Acrivon Therapeutics, Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. The company was incorporated in 2018 and is based in Watertown, Massachusetts.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2026-01-06$3.01 RISE2026-03-30$1.29 PEAK2026-05-04$2.17 118d | -57.1% 83d | Missed | Missed | — | — | +68.2% 35d | Missed |
DROP2026-01-06$3.01 RISE2026-02-24$1.50 PEAK2026-05-04$2.17 118d | -50.2% 49d | Missed | Missed | — | — | +44.7% 69d | Missed |
DROP2026-01-06$3.01 RISE2026-02-23$1.50 PEAK2026-05-04$2.17 118d | -50.2% 48d | Missed | Missed | — | — | +44.7% 70d | Missed |
DROP2026-01-06$3.01 RISE2026-02-11$1.50 PEAK2026-05-04$2.17 118d | -50.2% 36d | Missed | Missed | — | — | +44.7% 82d | Missed |
DROP2025-04-15$2.15 RISE2025-08-11$1.23 PEAK2025-11-03$2.33 202d | -42.8% 118d | Missed | Missed | — | — | +89.4% 84d | Missed |
DROP2025-02-05$6.97 RISE2025-05-30$1.05 PEAK2025-07-23$1.45 168d | -84.9% 114d | Missed | Missed | — | — | +38.1% 54d | Missed |
DROP2024-11-08$8.57 RISE2025-02-11$4.91 PEAK2025-02-20$5.85 104d | -42.7% 95d | Missed | Missed | — | — | +19.1% 9d | Missed |
DROP2024-08-29$9.98 RISE2024-12-30$5.41 PEAK2025-02-05$6.97 160d | -45.8% 123d | Missed | Missed | — | — | +28.8% 37d | Missed |
DROP2024-08-29$9.98 RISE2024-11-18$6.27 PEAK2024-11-29$7.58 92d | -37.2% 81d | Missed | Missed | — | — | +20.9% 11d | Missed |
DROP2024-08-29$9.98 RISE2024-10-03$6.89 PEAK2024-11-08$8.57 71d | -31.0% 35d | Missed | Missed | — | — | +24.4% 36d | Missed |
DROP2024-04-18$10.54 RISE2024-08-07$6.99 PEAK2024-08-29$9.98 133d | -33.7% 111d | Missed | Missed | — | — | +42.8% 22d | Missed |
DROP2024-04-18$10.54 RISE2024-06-27$5.76 PEAK2024-08-29$9.98 133d | -45.4% 70d | Missed | Missed | — | — | +73.3% 63d | Missed |
DROP2023-10-05$7.32 RISE2024-02-14$3.40 PEAK2024-04-18$10.54 196d | -53.6% 132d | Missed | Missed | — | — | +210.0% 64d | Missed |
DROP2023-07-19$13.17 RISE2023-11-21$3.63 PEAK2023-12-06$5.55 140d | -72.4% 125d | Missed | Missed | — | — | +52.9% 15d | Missed |
DROP2023-03-07$21.95 RISE2023-07-07$11.44 PEAK2023-07-19$13.17 134d | -47.9% 122d | Missed | Missed | — | — | +15.1% 12d | Missed |
1–15 / 18 1 / 2 | |||||||
No scored news yet for a sentiment trend.
Acrivon Therapeutics Inc:* Acrivon Therapeutics announces inducement grant under Nasdaq Listing Rule 5635...
Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.53) by 7.55 percent. This is a 3.92 percent increase over losses of $(0.51) per share
The registrational intent ACR-368 Phase 2b study is advancing with a prespecified simultaneous interim analysis and data update for both all-comer serous endometrial cancer arms in second half 2026 ...
Acrivon Therapeutics, Inc. ("Acrivon" or "Acrivon Therapeutics") (NASDAQ:ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics
Potent preclinical efficacy with durable immune memory observed in combinations of either ACR-368 or ACR-2316 with anti-PD-L1 and strong synergy of ACR-368 with Topoisomerase 1 inhibition Data...
Maturing data from the ongoing registrational intent Phase 2b ACR-368 study showed a confirmed overall response rate (cORR) of 52% in serous endometrial cancer (EC) Late-breaking oral presentation and corporate KOL panel at ESGO 2026 highlighted strong ACR-368 data in serous EC, a high unmet need subtype responsible for ~50% of EC mortality Initiated Arm 3 (ACR-368 + ultra low-dose gemcitabine) and adding Arm 4 (ACR-368) Phase 2b cohorts in all-comer (biopsy-independent) serous EC subjects Initi
Acrivon Therapeutics (NASDAQ:ACRV) reported quarterly losses of $(0.49) per share which beat the analyst consensus estimate of $(0.57) by 13.58 percent. This is a 18.33 percent increase over losses of $(0.60) per share
ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 (Topo 1) inhibitors, commonly used payloads in antibody-drug conjugates (ADCs) ACR-2316, a WEE1/PKMYT1 inhibitor currently in Phase 1, demonstrated complete and durable tumor regression in immunocompetent, syngeneic tumor mouse models in combination with anti-PD-L1 checkpoint inhibition WATERTOWN, Mass., March 17, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acri
ACR-368, a CHK1/2 inhibitor in a registrational-intent Phase 2b study, showed potent preclinical synergy with Topoisomerase 1 (Topo 1) inhibitors, commonly used payloads in antibody-drug conjugates (ADCs) ACR-2316,
Acrivon Therapeutics, Inc. (ACRV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Acrivon Therapeutics, Inc. (ACRV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Acrivon Therapeutics (NASDAQ:ACRV) hosted a webcast featuring a key opinion leader (KOL) panel focused on the company’s ongoing ACR-368 registrational-intent Phase 2B study in endometrial cancer, with particular attention on results in serous endometrial cancer. The panel discussion followed a late-
Acrivon Therapeutics (NASDAQ:ACRV) hosted a webcast featuring a key opinion leader (KOL) panel focused on the company’s ongoing ACR-368 registrational-intent Phase 2B study in endometrial cancer, with particular attention on results in serous endometrial cancer. The panel discussion followed a late-
WATERTOWN, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its proprietary Generative Phosphoproteomics AP3 (Acrivon Predictive Precision Proteomics) platform deployed for rational drug design and predictive clinical development, today announced the company’s president and chief executive officer, Peter Blume-Jensen, M.D., Ph.D.
Live webcast of event on February 27 at 8:00 a.m. ET will include participation of globally renowned gynecological oncology KOLs from the US and EU KOL panel to discuss maturing data from the ACR-368 registrational-intent trial, including recently disclosed promising results in serous EC, in the context of high unmet need in EC Panos Konstantinopoulos, M.D., Ph.D., Dana-Farber Cancer Institute, professor, Harvard Medical School, will deliver late-breaking oral presentation of ACR-368 interim cli
Wholly-owned laboratory has received CLIA certification from Massachusetts with full license to conduct patient testing and develop companion diagnostics Laboratory provides significant operational and strategic benefits for internal and future partnered assets WATERTOWN, Mass., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utilizing its propr
Globally recognized key opinion leader Panagiotis (Panos) Konstantinopoulos, M.D., Ph.D., Dana-Farber Cancer Institute, will highlight company’s recent interim clinical data from the ongoing, registrational-intent Phase 2b study of ACR-368 in subjects with endometrial cancerWATERTOWN, Mass., Jan. 23, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing precision medicines utiliz
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| ACRV | -23.44% | +4.58% | -33.61% | +52.38% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -26.41% | +10.29% | -30.17% | +39.69% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| Wellington | fundamental | 888.1K | $1.23M | 0.00% | Unchanged | 2026-03-31 |
| RenTech | quant | 758.4K | $1.05M | 0.00% | Added+19.6% | 2026-03-31 |
| TwoSigma | quant | 389.4K | $541.26K | 0.00% | Trimmed-33.4% | 2026-03-31 |
| StateStreet | passive | 67.1K | $93.33K | 0.00% | Unchanged | 2026-03-31 |
| FidelityFMR | fundamental | 9.4K | $13.10K | 0.00% | Added+9.3% | 2026-03-31 |
| Filed | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-05-26 | Blume-Jensen Peter | President and CEO | F Tax withholding | 13,729 | $1.79 | −$24.6K |
| 2026-05-20 | Blume-Jensen Peter | President and CEO | A Grant / award | 72,706 | — | +$0 |
| 2026-05-20 | Blume-Jensen Peter | President and CEO | A Grant / award | 180,095 | — | +$0 |
| 2026-05-20 | Devroe Eric | Chief Operating Officer | A Grant / award | 72,981 | — | +$0 |
| 2026-05-20 | Gamelin Erick | Chief Development Officer | A Grant / award | 38,584 | — | +$0 |
| 2026-05-20 | Levy Adam D. | Chief Financial Officer | A Grant / award | 46,167 | — | +$0 |
| 2026-05-20 | Miller Mary | Chief Legal Officer | A Grant / award | 49,830 | — | +$0 |
| 2026-05-20 | Mirza Mansoor Raza | Chief Medical Officer | A Grant / award | 38,817 | — | +$0 |
| 2026-05-20 | Peterson Katharine | Chief Accounting Officer | A Grant / award | 14,227 | — | +$0 |
| 2026-05-20 | BAUM CHARLES M | Director | A Grant / award | 9,366 | — | +$0 |
| 2026-05-20 | DiRocco Derek | Director | A Grant / award | 9,366 | — | +$0 |
| 2026-05-20 | Magovcevic-Liebisch Ivana | Director | A Grant / award | 9,366 | — | +$0 |
| 2026-05-20 | Palani Santhosh | Director | A Grant / award | 9,366 | — | +$0 |
| 2026-05-20 | Shacham Sharon | Director | A Grant / award | 9,366 | — | +$0 |
| 2026-05-20 | TOMSICEK MICHAEL JOHN | Director | A Grant / award | 9,366 | — | +$0 |
| 2026-05-20 | RA CAPITAL MANAGEMENT, L.P. | Director · 10% Owner | A Grant / award | 9,366 | — | +$0 |
| 2026-05-18 | Blume-Jensen Peter | President and CEO | F Tax withholding | 490 | $1.92 | −$941 |
| 2026-05-18 | Blume-Jensen Peter | President and CEO | F Tax withholding | 1,253 | $1.92 | −$2.4K |
| 2026-05-18 | Devroe Eric | Chief Operating Officer | F Tax withholding | 613 | $1.92 | −$1.2K |
| 2026-05-18 | Gamelin Erick | Chief Development Officer | F Tax withholding | 404 | $1.92 | −$776 |
| 2026-05-18 | Miller Mary | Chief Legal Officer | F Tax withholding | 184 | $1.92 | −$353 |
| 2026-05-18 | Peterson Katharine | Chief Accounting Officer | F Tax withholding | 99 | $1.92 | −$190 |
| 2026-04-23 | RA CAPITAL MANAGEMENT, L.P. | Director · 10% Owner | A Grant / award | 3,888,888 | $1.80 | +$7.00M |
| 2026-04-21 | Miller Mary | Chief Legal Officer | F Tax withholding | 558 | $1.78 | −$993 |
| 2026-03-03 | Blume-Jensen Peter | President and CEO | A Grant / award(deriv) | 185,495 | — | +$0 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-05-13 | -0.52 | -0.49 | +5.77% |
| 2026-03-19 | -0.46 | -0.49 | -7.40% |
| 2025-11-13 | -0.58 | -0.47 | +18.97% |
| 2025-08-14 | -0.58 | — | — |
| 2025-08-13 | -0.59 | -0.55 | +6.07% |
| 2025-05-14 | -0.65 | -0.51 | +21.05% |
| 2025-03-27 | -0.70 | -0.54 | +23.30% |
| 2024-11-13 | -0.59 | -0.59 | +0.24% |
| 2024-08-13 | -0.57 | -0.52 | +8.77% |
| 2024-05-14 | -0.85 | -0.73 | +14.62% |
| 2024-03-28 | -0.69 | -0.87 | -26.45% |
| 2023-11-09 | -0.69 | -0.66 | +4.90% |
| 2023-08-11 | -0.62 | -0.63 | -1.29% |
| 2023-05-09 | -0.62 | -0.58 | +6.45% |
| 2023-03-28 | -0.81 | -0.80 | +1.23% |
| 2022-12-15 | -0.92 | -5.17 | -461.96% |